Proprotein convertase 7 (PCSK7) reduces apoA‐V levels-Reference-Cited by-同舟云学术

Proprotein convertase 7 (PCSK7) reduces apoA‐V levels

Published:2020-01-29 Issue:16 Volume:287 Page:3565-3578
ISSN:1742-464X
Container-title:The FEBS Journal
language:en
Short-container-title:FEBS J

Author:

Ashraf Yahya¹,Duval Stéphanie¹,Sachan Vatsal¹,Essalmani Rachid¹,Susan‐Resiga Delia¹,Roubtsova Anna¹,Hamelin Josée¹,Gerhardy Stefan²,Kirchhofer Daniel²,Tagliabracci Vincent S.³,Prat Annik¹,Kiss Robert Scott⁴,Seidah Nabil G.¹^ORCID

Affiliation:

1. Laboratory of Biochemical Neuroendocrinology Clinical Research Institute of Montreal QC Canada

2. Early Discovery Biochemistry Genentech Inc. South San Francisco CA USA

3. Department of Molecular Biology University of Texas Southwestern Medical Center Dallas TX USA

4. Research Institute McGill University Health Center Montreal QC Canada

Funder

Institute of Nutrition, Metabolism and Diabetes

Publisher

Wiley

Subject

Cell Biology,Molecular Biology,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/febs.15212

Reference42 articles.

1. cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases.

2. The biology and therapeutic targeting of the proprotein convertases

3. The Proprotein Convertase PC7

4. Implication of the proprotein convertases in iron homeostasis: Proprotein convertase 7 sheds human transferrin receptor 1 and furin activates hepcidin

5. Association of Low-Frequency and Rare Coding-Sequence Variants with Blood Lipids and Coronary Heart Disease in 56,000 Whites and Blacks

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK7: A novel regulator of apolipoprotein B and a potential target against non-alcoholic fatty liver disease;Metabolism;2024-01

2. Regulation of secretory pathway kinase or kinase-like proteins in human cancers;Frontiers in Immunology;2023-02-07

3. Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease;Frontiers in Pharmacology;2022-09-15

4. Can PCSK7 be A New Pharmaceutical Target?;Journal of Atherosclerosis and Thrombosis;2022-09-01

5. Post-Transcriptional Effects of miRNAs on PCSK7 Expression and Function: miR-125a-5p, miR-143-3p, and miR-409-3p as Negative Regulators;Metabolites;2022-06-23